In the last 15-20 years new tools in diabetes therapy have emerged such as Continuous Glucose Monitoring (CGM) and Continuous Subcutaneous Insulin Infusion (CSII) which are destined to substitute Self Monitored Blood Glucose (SMBG) and Multiple Daily Injection (MDI) technologies especially in the management of type 1 diabetes.
In order to determine the appropriate meal insulin bolus, it is important to know the subject specific insulin sensitivity (SI), i.e., the ability of insulin to stimulate glucose utilization and inhibit glucose production.
SI is traditionally estimated through hyperinsulinemic euglycemic clamp, intravenous, oral and/or meal glucose tolerance tests. However, all these methodologies require to measure plasma glucose and insulin levels in hospitalized settings and, therefore, cannot be used in everyday life.
The patent relates to a method to estimate SI from CGM and CSII data. The method can be easily implemented with the above systems coming from different vendors, and it allows to improve the quality of life diabetic patients.
Furthermore, the invention can be implemented in portable advisory systems and in artificial pancreas, which already incorporate the devices to evaluate SI and may benefit of registering insulin sensitivity pattern during the day.